The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Omacetaxine mepesuccinate in chronic phase chronic myeloid leukemia (CML-CP): A post hoc analysis of myelosuppression.
Luke Paul Akard
Consultant or Advisory Role - Bristol-Myers Squibb; Eisai; Millennium; Novartis; Teva
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Teva
Hagop M. Kantarjian
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer
Franck E. Nicolini
Consultant or Advisory Role - ARIAD; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Research Funding - Novartis
Meir Wetzler
Consultant or Advisory Role - Teva
Research Funding - Bristol-Myers Squibb
Jeffrey Howard Lipton
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Stock Ownership - ARIAD
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Michele Baccarani
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Hanna Jean Khoury
No relevant relationships to disclose
Adam Craig
Consultant or Advisory Role - Teva
Jorge E. Cortes
Consultant or Advisory Role - ARIAD; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; ChemGenex; Novartis; Pfizer